ACCELERATE DRUG DISCOVERIES USING GENOMICS AND COMPUTING

RNA splicing is a fundamental mechanism in molecular biology in which segments of messenger RNAs (mRNAs) are either retained or cut-out from the final transcript in a context dependent manner. The ability to selectively include or exclude portions of an mRNA allows the production of multiple mRNAs and hence multiple proteins from a single gene.

Founded by world-renowned computational and experimental RNA biologists, Panorama Medicine's proprietary platforms integrate genomics, drug screening, big data, and artificial intelligence to develop therapeutic interventions for RNA splicing defects in a wide variety of diseases.

 
 

TEAM

SCIENTIFIC TEAM

Haishan Xiong, Ph.D., MBA
Chief Executive Officer
Boris Zinshteyn, Ph.D.
Director of Research
Zhicheng Pan, Ph.D.
Computational Biologist
READ BIO
James Aykit
Molecular Biologist
READ BIO
Madelyn Smith
Molecular Biologist
Ariana Waters
Molecular Biologist
READ BIO

FOUNDERS

Douglas Black, Ph.D.
Co-founder
Yi Xing, Ph.D.
Co-founder

ADVISORS & BOARD

Beverly Davidson, Ph.D.
Scientific Advisor
READ BIO
Hui Kang
Board Member
READ BIO
Sean Peng
Board Member
 

LATEST NEWS

INVESTORS

mmexport1643169971199.png
wi-harper-group.jpg
image (2)_edited.png
20180725190411805.png
zhen-fund_owler_20160227_001955_original
image (3).png

JOIN OUR TEAM

Panorama is always looking for talented individuals interested in working to improve the lives of people with severe genetic disease.

Consider joining our team.
 

 

CONTACT US

Screen Shot 2019-11-20 at 11.02.23.png

3675 Market St, Philadelphia, PA 19104